Personalized mRNA Cancer Vaccines Move Closer to Long-Term Clinical Use

Five-year melanoma data and a growing wave of clinical studies are strengthening the case for personalized mRNA cancer vaccines. Unlike preventive vaccines, these treatments are built from each patient’s tumor mutations and are designed to train the immune system after cancer has appeared.